DOSIsoft

Coral Gables,  FL 
United States
http://www.dosisoft.com

• Booth: 1138

PLANET® Dose: Patient-specific, Multi-radionuclide (90Y/177Lu/131I/166Ho) & Theranostics platform for voxel-based personalized dosimetry (SIRT & MRT).

DOSIsoft is a leading provider of dosimetry software solutions in Radiation Oncology and Nuclear Medicine, dedicated to improving cancer patient safety and treatment quality. Through continuous innovation, DOSIsoft designs, develops, delivers, and supports some of the most advanced patient-specific quality assurance and medical imaging tools—successfully adopted by over 600 hospital centers across 60 countries worldwide. With FDA 510(k) clearance for U.S. marketing, the latest release—PLANET® Onco Dose v3.2—is a next-generation dosimetry platform built to support multi-radionuclide capabilities, diverse workflows, and a wide range of therapy applications. The software features advanced voxel-based dose computation for 90Y-SIRT as well as 177Lu and 131I-based MRT therapies, with the flexibility to incorporate emerging beta and gamma emitters. Clinicians can choose between multi-time point or the newly introduced single-time point dosimetry workflows—streamlining clinical processes, reducing workload, and improving patient comfort while maintaining high dosimetric accuracy. DOSIsoft is a spin-off between Gutave Roussy and Curie Institute, with offices in France, Argentina, and the U.S., and a broad network of distributors. DOSIsoft collaborates with leading cancer institutes and research centers worldwide.

Brands: PLANET Dose - Patient QA with ThinkQA Secondary Dose Check, EPIbeam pretreatment verification and EPIgray® in vivo dosimetry.

 Press Releases

• New FDA 510(k) Clearance for PLANET® Onco Dose (May 05, 2025)

  DOSIsoft, SA, a leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, is proud to announce its latest product release, PLANET^® Onco Dose version 3.2 received FDA 510(k) Clearance on March 14, 2025 from the US Food and Drug Administration, following its EU MDR CE Mark certification.

  The novel PLANET^® platform is designed to incorporate a multi-radionuclide approach, implement multi-workflow solutions, and support multi-therapy applications for both SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) while ensuring compliance with U.S. standards.

 Products